EUVIMEDEUVIMED entdecken
Crossref

Design of Selective PARP-1 Inhibitors and Antitumor Studies

Yiting Zhang iD, Xiangqian Li, Fang Liu, Xiaoyi Bai, Xiaochun Liu, Hao Sun, Chenxia Gao, Yuxi Lin, Pan Xing, Jiqiang Zhu, Ruihua Liu, Zemin Wang und 2 weitere

Journal of Medicinal Chemistry · 13.06.2024 · 67 (11) · 8877-8901

DOI: 10.1021/acs.jmedchem.3c02460 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 22.05.2024. Verfasst von Yiting Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Antineoplastic Agents, Drug Design, Poly (ADP-Ribose) Polymerase-1. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of Shandong Province, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Designing selective PARP-1 inhibitors has become a new strategy for anticancer drug development. By sequence comparison of PARP-1 and PARP-2, we identified a possible selective site (S site) consisting of several different amino acid residues of α-5 helix and D-loop. Targeting this S site, 140 compounds were designed, synthesized, and characterized for their anticancer activities and mechanisms. Compound I16 showed the highest PARP-1 enzyme inhibitory activity (IC50 = 12.38 ± 1.33 nM) and optimal selectivity index over PARP-2 (SI = 155.74). Oral administration of I16 (25 mg/kg) showed high inhibition rates of Hela and SK-OV-3 tumor cell xenograft models, both of which were higher than those of the oral positive drug Olaparib (50 mg/kg). In addition, I16 has an excellent safety profile, without significant toxicity at high oral doses. These findings provide a novel design strategy and chemotype for the development of safe, efficient, and highly selective PARP-1 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsDrug DesignPoly (ADP-Ribose) Polymerase-1HumansAnimalsMiceStructure-Activity RelationshipCell Line, TumorMice, NudeFemaleXenograft Model Antitumor AssaysHeLa CellsMolecular Docking SimulationMice, Inbred BALB CCell ProliferationPhthalazines

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsPoly (ADP-Ribose) Polymerase-1PARP1 protein, humanPhthalazines

Autor:innen und Institutionen

  • State Key Laboratory of Microbial Technology, Shandong University, Qingdao 266237, China.
  • Laboratory of Marine Drugs and Biological Products, Pilot National Laboratory for Marine Science and Technology, Qingdao 266237, China.
  • Marine Biomedical Research Institute of Qingdao, Qingdao 266071, China.
  • Shandong Linghai Biotechnology Co.Ltd., Jinan 250299, Shandong, P. R. China.
  • Key Laboratory of Marine Ecology and Environmental Sciences, Institute of Oceanology, Chinese Academy of Sciences, Qingdao 266071, Shandong, China.

ORCID-Profile: Yiting Zhang, Dayong Shi

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of Shandong Province
  • Chinese Academy of Sciences
  • Shandong Province
  • Qingdao Emerging Industry Cultivation Project

Zitieren

APA

Zhang, Y., Li, X., Liu, F., Bai, X., Liu, X., Sun, H., Gao, C., Lin, Y., Xing, P., Zhu, J., Liu, R., Wang, Z., Dai, J., & Shi, D. (2024). Design of Selective PARP-1 Inhibitors and Antitumor Studies. Journal of Medicinal Chemistry, 67(11), 8877-8901. https://doi.org/10.1021/acs.jmedchem.3c02460

Vancouver

Zhang Y, Li X, Liu F, Bai X, Liu X, Sun H, et al. Design of Selective PARP-1 Inhibitors and Antitumor Studies. Journal of Medicinal Chemistry. 2024;67(11):8877-8901. doi:10.1021/acs.jmedchem.3c02460

BibTeX
@article{Zhang2024,
  author = {Zhang, Yiting and Li, Xiangqian and Liu, Fang and Bai, Xiaoyi and Liu, Xiaochun and Sun, Hao and Gao, Chenxia and Lin, Yuxi and Xing, Pan and Zhu, Jiqiang and Liu, Ruihua and Wang, Zemin and Dai, Jiajia and Shi, Dayong},
  title = {Design of Selective PARP-1 Inhibitors and Antitumor Studies},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {11},
  pages = {8877--8901},
  doi = {10.1021/acs.jmedchem.3c02460}
}
Kostenlos starten →